Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Difference in Survival in Early Kidney after Liver Transplant Compared with Simultaneous Liver-Kidney Transplantation: Evaluating the Potential of the "Safety Net".

Jay CL, Washburn WK, Rogers J, Harriman D, Heimbach J, Stratta RJ.

J Am Coll Surg. 2020 Jan 30. pii: S1072-7515(20)30102-2. doi: 10.1016/j.jamcollsurg.2019.12.017. [Epub ahead of print]

PMID:
32007536
2.

A Survey of Current Procurement Travel Practices, Accident Frequency, and Perceptions of Safety.

Schenk AD, Washburn WK, Adams AB, Lynch RJ.

Transplant Direct. 2019 Sep 27;5(10):e494. doi: 10.1097/TXD.0000000000000942. eCollection 2019 Oct.

3.

[D-Ala2, D-Leu5] Enkephalin Improves Liver Preservation During Normothermic Ex Vivo Perfusion.

Beal EW, Kim JL, Reader BF, Akateh C, Maynard K, Washburn WK, Zweier JL, Whitson BA, Black SM.

J Surg Res. 2019 Sep;241:323-335. doi: 10.1016/j.jss.2019.04.010. Epub 2019 May 6.

PMID:
31071481
4.

Outcomes of domino liver transplantation compared to deceased donor liver transplantation: a propensity-matching approach.

Geyer ED, Burrier C, Tumin D, Hayes D Jr, Black SM, Washburn WK, Tobias JD.

Transpl Int. 2018 Nov;31(11):1200-1206. doi: 10.1111/tri.13291. Epub 2018 Jul 17.

5.

Medicaid Participation among Liver Transplant Candidates after the Affordable Care Act Medicaid Expansion.

Tumin D, Beal EW, Mumtaz K, Hayes D Jr, Tobias JD, Pawlik TM, Washburn WK, Black SM.

J Am Coll Surg. 2017 Aug;225(2):173-180.e2. doi: 10.1016/j.jamcollsurg.2017.05.004. Epub 2017 May 19.

PMID:
28529137
6.

Mechanisms for Hepatobiliary Toxicity in Rats Treated with an Antagonist of Melanin Concentrating Hormone Receptor 1 (MCHR1).

Otieno MA, Bhaskaran V, Janovitz E, Callejas Y, Foster WB, Washburn W, Megill JR, Lehman-McKeeman L, Gemzik B.

Toxicol Sci. 2017 Feb;155(2):379-388. doi: 10.1093/toxsci/kfw216. Epub 2016 Oct 20.

PMID:
28025230
7.

Synthesis and Antiobesity Properties of 6-(4-Chlorophenyl)-3-(4-((3,3-difluoro-1-hydroxycyclobutyl)methoxy)-3-methoxyphenyl)thieno[3,2-d]pyrimidin-4(3H)-one (BMS-814580): A Highly Efficacious Melanin Concentrating Hormone Receptor 1 (MCHR1) Inhibitor.

Ahmad S, Washburn WN, Hernandez AS, Bisaha S, Ngu K, Wang W, Pelleymounter MA, Longhi D, Flynn N, Azzara AV, Rohrbach K, Devenny J, Rooney S, Thomas M, Glick S, Godonis H, Harvey S, Zhang H, Gemzik B, Janovitz EB, Huang C, Zhang L, Robl JA, Murphy BJ.

J Med Chem. 2016 Oct 13;59(19):8848-8858. Epub 2016 Sep 15.

PMID:
27564419
8.

TGF-β1 promotes acinar to ductal metaplasia of human pancreatic acinar cells.

Liu J, Akanuma N, Liu C, Naji A, Halff GA, Washburn WK, Sun L, Wang P.

Sci Rep. 2016 Aug 3;6:30904. doi: 10.1038/srep30904.

9.

Medicaid enrollment after liver transplantation: Effects of medicaid expansion.

Tumin D, Hayes D Jr, Washburn WK, Tobias JD, Black SM.

Liver Transpl. 2016 Aug;22(8):1075-84. doi: 10.1002/lt.24480.

10.

An early look at the Organ Procurement and Transplantation Network explant pathology form data.

Harper AM, Edwards E, Washburn WK, Heimbach J.

Liver Transpl. 2016 Jun;22(6):757-64. doi: 10.1002/lt.24441.

11.

Non-basic azolotriazinone MCHR1 antagonists for the treatment of obesity: An empirical brain-exposures-driven candidate selection for in vivo efficacy studies.

Devasthale P, Wang W, Mignone J, Renduchintala K, Radhakrishnan S, Dhanapal J, Selvaraj J, Kuppusamy R, Pelleymounter MA, Longhi D, Huang N, Flynn N, Azzara AV, Rohrbach K, Devenny J, Rooney S, Thomas M, Glick S, Godonis H, Harvey S, Cullen MJ, Zhang H, Caporuscio C, Stetsko P, Grubb M, Huang C, Zhang L, Freeden C, Murphy BJ, Robl JA, Washburn WN.

Bioorg Med Chem Lett. 2015 Oct 15;25(20):4412-8. doi: 10.1016/j.bmcl.2015.09.018. Epub 2015 Sep 8.

PMID:
26386604
12.

Dihydropyrrolopyrazol-6-one MCHR1 antagonists for the treatment of obesity: Insights on in vivo efficacy from a novel FLIPR assay setup.

Devasthale P, Wang W, Hernandez AS, Moore F, Renduchintala K, Sridhar R, Pelleymounter MA, Longhi D, Huang N, Flynn N, Azzara AV, Rohrbach K, Devenny J, Rooney S, Thomas M, Glick S, Godonis H, Harvey S, Cullen MJ, Zhang H, Caporuscio C, Stetsko P, Grubb M, Huang C, Zhang L, Freeden C, Li YX, Murphy BJ, Robl JA, Washburn WN.

Bioorg Med Chem Lett. 2015 Jul 15;25(14):2793-9. doi: 10.1016/j.bmcl.2015.05.008. Epub 2015 May 15.

PMID:
26022839
13.

Identification of a nonbasic melanin hormone receptor 1 antagonist as an antiobesity clinical candidate.

Washburn WN, Manfredi M, Devasthale P, Zhao G, Ahmad S, Hernandez A, Robl JA, Wang W, Mignone J, Wang Z, Ngu K, Pelleymounter MA, Longhi D, Zhao R, Wang B, Huang N, Flynn N, Azzara AV, Barrish JC, Rohrbach K, Devenny JJ, Rooney S, Thomas M, Glick S, Godonis HE, Harvey SJ, Cullen MJ, Zhang H, Caporuscio C, Stetsko P, Grubb M, Maxwell BD, Yang H, Apedo A, Gemzik B, Janovitz EB, Huang C, Zhang L, Freeden C, Murphy BJ.

J Med Chem. 2014 Sep 25;57(18):7509-22. doi: 10.1021/jm500026w. Epub 2014 Sep 9.

PMID:
25165888
14.

Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients.

Alloway RR, Eckhoff DE, Washburn WK, Teperman LW.

Liver Transpl. 2014 May;20(5):564-75. doi: 10.1002/lt.23844. Epub 2014 Mar 26.

15.

Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.

Washburn WN, Poucher SM.

Expert Opin Investig Drugs. 2013 Apr;22(4):463-86. doi: 10.1517/13543784.2013.774372. Epub 2013 Mar 1. Review.

PMID:
23452053
16.

Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents.

Washburn WN.

Expert Opin Ther Pat. 2012 May;22(5):483-94. doi: 10.1517/13543776.2012.680437. Review.

PMID:
22583331
17.

Estimation of the extent of in vivo formation of a mutagenic aromatic amine from a potent thyromimetic compound: correlation of in vitro and in vivo findings.

Behnia K, Cornelius G, Wang J, Shipkova P, Johnghar S, Washburn W, Brigance R, Stetsko P, Henwood A, Wojciechowski JP, Marathe P, Rodrigues AD, Humphreys WG.

Chem Res Toxicol. 2011 Jun 20;24(6):905-12. doi: 10.1021/tx200087q. Epub 2011 Jun 1.

PMID:
21574629
18.

Center-based differences in liver quality: why do they exist?

Feng S, Washburn WK.

Am J Transplant. 2011 May;11(5):884-5. doi: 10.1111/j.1600-6143.2011.03494.x. Epub 2011 Apr 5. No abstract available.

19.

High-grade microsteatosis and delay in hepatic function after orthotopic liver transplantation.

Sharkey FE, Lytvak I, Prihoda TJ, Speeg KV, Washburn WK, Halff GA.

Hum Pathol. 2011 Sep;42(9):1337-42. doi: 10.1016/j.humpath.2010.12.004. Epub 2011 Mar 21.

PMID:
21420717
20.

Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report.

Wang Y, Speeg KV, Washburn WK, Halff G.

World J Gastroenterol. 2010 Nov 21;16(43):5518-22.

21.

An early regional experience with expansion of Milan Criteria for liver transplant recipients.

Guiteau JJ, Cotton RT, Washburn WK, Harper A, O'Mahony CA, Sebastian A, Cheng S, Klintmalm G, Ghobrial M, Halff G, Mieles L, Goss J.

Am J Transplant. 2010 Sep;10(9):2092-8. doi: 10.1111/j.1600-6143.2010.03222.x.

22.

In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.

Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, Komoroski B, Kasichayanula S, Discenza L, Washburn W, Meng W, Ellsworth BA, Whaley JM, Humphreys WG.

Drug Metab Dispos. 2010 Mar;38(3):405-14. doi: 10.1124/dmd.109.029165. Epub 2009 Dec 8.

PMID:
19996149
23.

Factors influencing liver transplant length of stay at two large-volume transplant centers.

Washburn WK, Meo NA, Halff GA, Roberts JP, Feng S.

Liver Transpl. 2009 Nov;15(11):1570-8. doi: 10.1002/lt.21858.

24.

Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents.

Washburn WN.

Expert Opin Ther Pat. 2009 Nov;19(11):1485-99. doi: 10.1517/13543770903337828. Review.

PMID:
19852718
25.

Liver and intestine transplantation in the United States 1998-2007.

Berg CL, Steffick DE, Edwards EB, Heimbach JK, Magee JC, Washburn WK, Mazariegos GV.

Am J Transplant. 2009 Apr;9(4 Pt 2):907-31. doi: 10.1111/j.1600-6143.2009.02567.x.

26.

Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.

Washburn WN.

J Med Chem. 2009 Apr 9;52(7):1785-94. doi: 10.1021/jm8013019. Review. No abstract available.

PMID:
19243175
27.

Surgical treatment of an extrarenal pseudoaneurysm after kidney transplantation.

Sharron JA, Esterl RM, Washburn WK, Abrahamian GA.

Vasc Endovascular Surg. 2009 Jun-Jul;43(3):317-21. doi: 10.1177/1538574409331697. Epub 2009 Feb 17.

PMID:
19223384
28.

Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2.

Ellsworth BA, Meng W, Patel M, Girotra RN, Wu G, Sher PM, Hagan DL, Obermeier MT, Humphreys WG, Robertson JG, Wang A, Han S, Waldron TL, Morgan NN, Whaley JM, Washburn WN.

Bioorg Med Chem Lett. 2008 Sep 1;18(17):4770-3. doi: 10.1016/j.bmcl.2008.07.109. Epub 2008 Jul 31.

PMID:
18707880
29.

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.

Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM.

Diabetes. 2008 Jun;57(6):1723-9. doi: 10.2337/db07-1472. Epub 2008 Mar 20.

30.

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Morrison EP, Biller SA, Zahler R, Deshpande PP, Pullockaran A, Hagan DL, Morgan N, Taylor JR, Obermeier MT, Humphreys WG, Khanna A, Discenza L, Robertson JG, Wang A, Han S, Wetterau JR, Janovitz EB, Flint OP, Whaley JM, Washburn WN.

J Med Chem. 2008 Mar 13;51(5):1145-9. doi: 10.1021/jm701272q. Epub 2008 Feb 9.

PMID:
18260618
31.

Reply: geographic disparities and deceased donor liver transplantation within a single UNOS region.

Goss JA, Barshes NR, Washburn WK.

Liver Transpl. 2007 Dec;13(12):1760; author reply 1761. No abstract available.

32.

Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study.

Klintmalm GB, Washburn WK, Rudich SM, Heffron TG, Teperman LW, Fasola C, Eckhoff DE, Netto GJ, Katz E.

Liver Transpl. 2007 Nov;13(11):1521-31.

33.

Thyroid receptor ligands. Part 8: Thyromimetics derived from N-acylated-alpha-amino acid derivatives displaying modulated pharmacological selectivity compared with KB-141.

Garg N, Li YL, Garcia Collazo AM, Litten C, Ryono DE, Zhang M, Caringal Y, Brigance RP, Meng W, Washburn WN, Agback P, Mellström K, Rehnmark S, Rahimi-Ghadim M, Norin T, Grynfarb M, Sandberg J, Grover G, Malm J.

Bioorg Med Chem Lett. 2007 Aug 1;17(15):4131-4. Epub 2007 May 21.

PMID:
17543524
34.

Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformations.

Washburn WN, Harper TW, Wu G, Godfrey JD, McCann P, Girotra R, Shao C, Zhang H, Gavai A, Mikkilineni A, Dejneka T, Ahmed S, Caringal Y, Hangeland J, Zhang M, Cheng PT, Russell AD, Skwish S, Slusarchyk DA, Allen GT, Frohlich BH, Abboa-Offei BE, Cap M, Waldron TL, George RJ, Tesfamariam B, Dickinson KE, Seymour AA, Sher PM.

Bioorg Med Chem Lett. 2007 Aug 1;17(15):4290-6. Epub 2007 May 16.

PMID:
17533126
35.

Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series.

Ellsworth BA, Wang Y, Zhu Y, Pendri A, Gerritz SW, Sun C, Carlson KE, Kang L, Baska RA, Yang Y, Huang Q, Burford NT, Cullen MJ, Johnghar S, Behnia K, Pelleymounter MA, Washburn WN, Ewing WR.

Bioorg Med Chem Lett. 2007 Jul 15;17(14):3978-82. Epub 2007 Apr 29.

PMID:
17513109
36.

Geographic disparities in deceased donor liver transplantation within a single UNOS region.

Barshes NR, Becker NS, Washburn WK, Halff GA, Aloia TA, Goss JA.

Liver Transpl. 2007 May;13(5):747-51.

37.

Model for end-stage liver disease (MELD) exception for Budd-Chiari syndrome.

Washburn WK, Gish RG, Kamath PS.

Liver Transpl. 2006 Dec;12(12 Suppl 3):S93-4. No abstract available. Erratum in: Liver Transpl. 2007 Mar;13(3):472. Liver Transpl. 2008 Sep;14(9):1386.

38.

Model for end-stage liver disease (MELD) exception for severe pruritus.

Washburn WK, Gish RG.

Liver Transpl. 2006 Dec;12(12 Suppl 3):S119. No abstract available. Erratum in: Liver Transpl. 2008 Sep;14(9):1386.

39.

Use of split-liver allografts does not impair pediatric recipient growth.

Mejia A, Barshes N, Halff G, Goss J, Washburn WK.

Liver Transpl. 2007 Jan;13(1):145-8.

40.

Impact of recipient MELD score on resource utilization.

Washburn WK, Pollock BH, Nichols L, Speeg KV, Halff G.

Am J Transplant. 2006 Oct;6(10):2449-54. Epub 2006 Aug 1.

41.

A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic study.

Washburn WK, Teperman LW, Heffron TG, Douglas DD, Gay S, Katz E, Klintmalm GB.

Liver Transpl. 2006 Apr;12(4):585-91.

42.

Split-liver transplantation using the left lateral segment: a collaborative sharing experience between two distant centers.

Lee TC, Barshes NR, Washburn WK, Halff GA, Carter BA, Karpen SJ, Bristow LJ, Scott JD, Goss JA.

Am J Transplant. 2005 Jul;5(7):1646-51.

44.

Severe, late-onset graft-versus-host disease in a liver transplant recipient documented by chimerism analysis.

Pollack MS, Speeg KV, Callander NS, Freytes CO, Espinoza AA, Esterl RM, Abrahamian GA, Washburn WK, Halff GA.

Hum Immunol. 2005 Jan;66(1):28-31.

PMID:
15620459
45.

BMS-201620: a selective beta 3 agonist.

Washburn WN, Sun CQ, Bisacchi G, Wu G, Cheng PT, Sher PM, Ryono D, Gavai AV, Poss K, Girotra RN, McCann PJ, Mikkilineni AB, Dejneka TC, Wang TC, Merchant Z, Morella M, Arbeeny CM, Harper TW, Slusarchyk DA, Skwish S, Russell AD, Allen GT, Tesfamariam B, Frohlich BH, Abboa-Offei BE, Cap M, Waldron TL, George RJ, Young D, Dickinson KE, Seymour AA.

Bioorg Med Chem Lett. 2004 Jul 5;14(13):3525-9.

PMID:
15177466
46.

Use of a silastic silo for closure of the abdominal wall in a pediatric patient receiving a cadaveric split liver.

Jones WT, Ratner I, Abrahamian G, Washburn WK, Esterl R, Neigut D, Halff G.

J Pediatr Surg. 2003 Oct;38(10):E20-2.

PMID:
14577099
47.

Enlargement of the cadaveric-liver donor pool using in-situ split-liver transplantation despite complex hepatic arterial anatomy.

Nunez A, Goodpastor SE, Goss JA, Washburn WK, Halff GA.

Transplantation. 2003 Oct 15;76(7):1134-6. No abstract available.

PMID:
14557768
48.

Radiofrequency tissue ablation: effect of hepatic blood flow occlusion on thermal injuries produced in cirrhotic livers.

Washburn WK, Dodd GD 3rd, Kohlmeier RE, McCoy VA, Napier DH, Hubbard LG, Halff GA, Esterl RM, Cigarroa FG, Sharkey FE.

Ann Surg Oncol. 2003 Aug;10(7):773-7.

PMID:
12900368
49.

Transjugular intrahepatic portosystemic shunt creation in a patient with situs inversus.

Postoak DW, Ferral H, Washburn WK, Speeg KV, Wholey MH.

J Vasc Interv Radiol. 2002 Jul;13(7):755-6. No abstract available.

PMID:
12119339
50.

Sonographically observed echogenic response during intraoperative radiofrequency ablation of cirrhotic livers: pathologic correlation.

Leyendecker JR, Dodd GD 3rd, Halff GA, McCoy VA, Napier DH, Hubbard LG, Chintapalli KN, Chopra S, Washburn WK, Esterl RM, Cigarroa FG, Kohlmeier RE, Sharkey FE.

AJR Am J Roentgenol. 2002 May;178(5):1147-51.

PMID:
11959720

Supplemental Content

Loading ...
Support Center